Rice University competition doles out nearly $2M in cash prizes to student startups

winner, winner

The 22nd annual Rice Business Plan Competition named its winners across life science, clean energy, software, and more. Photo via Rice University/Twitter

Rice University brought back its international student startup competition to its in-person format in a big way, giving out nearly $2 million in investment plus thousands more in-kind prizes to over a dozen winning teams.

The 2022 Rice Business Plan Competition took place April 7-9 on campus, ending in a banquet and awards presentation at the Marriott Marquis on Saturday. Earlier this year, Rice announced the 42 student teams competing for the awards. The student competitors represent 31 universities — including three from European universities. The 42 teams were narrowed down from over 400 applicants and divided into five categories: energy, cleantech and sustainability; life sciences and health care solutions; consumer products and services; hard tech; and digital enterprise.

Over 250 judges, mentors, and investors were involved in the competition, naming seven finalists — each receiving thousands of dollars in investment funding.

Here were this year's finalists — and what they walked away with:

  • LIDROTEC from RWTH Aachen University, a cutting-edge machine that can better cut microchips for the semiconductor industry, is the big winner this year, taking home the $350,000 GOOSE Capital Investment Grand Prize. The team also won: the Softeq Venture Studio Prize ($50,000 cash, $75,000 in-kind), the TiE Houston Angels Investment Prize ($100,000), RBPC Alumnus, Thomas Healy, Investment Prize ($50,000), the Eagle Investors Prise ($5,000), Best Elevator Pitch - Hard Tech ($500), and RG Advisors CFO Consulting In-Kind Prize. The company also received a $6,700 in-kind prize from BakerBotts and an in-kind $25,000 from RG Advisory. The company's prize totaled over $682,200 in investment and in-kind awards.
  • The second place winner was Hoth Intelligence of University of Pittsburgh, an artificial intelligence platform for health care providers, securing a $100,000 investment prize. The company also won the Owl Investment Prize ($155,000), the HAN Investment Prize ($100,000), and the Pearland EDC Spirit of Entrepreneurship Prize ($25,000). The company also received a a $6,700 in-kind prize from BakerBotts. The company's prize totaled $386,700 in investment awards.
  • Invitris from the Technical University of Munich — a synthetic biology startup targeting antibiotic-resistant bacteria — won third place, which came with a $50,000 award. The team also won the nCourage Courageous Women Entrepreneur Investment Prize ($40,000), the Best Elevator Pitch - Life Science award ($500), and a $6,700 in-kind prize from BakerBotts. bringing its total earnings to $97,200.
  • Winning fourth place and a $5,000 prize was LymphaSense of Johns Hopkins, a medical device startup that's created a wearable lymphedema detection device for at-risk patients. The company also won the TMC Innovation Healthcare Investment Prize ($250,000 and entry into the TMC accelerator) and the Nixon Institute Prize ($3,000). The company's total winnings was $258,000.
  • INIA Biosciences from Boston University — a health tech startup that's created a bioelectric wearable device for kidney donor recipients — won fifth place and $5,000 in prize money.
  • The sixth place winner was Bold Move Beverages, a canned coffee cocktail company from the University of Texas at Austin, which won $5,000 for placing sixth and $10,000 from the RBPC Alumnus, Thomas Healy, Investment Prize. The company won a total of $15,000.
  • Lastly for the finalists, Anise Health of Harvard University, a digital health startups with an inclusive, data-driven platform for culturally-adapted mental health treatment, won seventh place and the $5,000 prize. The company also won first place in the wildcard round, which came with a $2,000 Edward H. Molter Memorial Prize. Anise walked away with $7,000 total.
Several companies won monetary prizes outside of the seven finalists. Here's what other student-founded companies in the competition won:
  • Mallard Bay Outdoors from Louisiana State University, an online marketplace for securely booking outdoor activities, won $216,500 in cash and in-kind prizes. The company won the Owl Investment Prize ($65,000), the Softeq Venture Studio Prize ($50,000 cash, $75,000 in-kind), the RBPC Alumnus, Thomas Healy, Investment Prize ($25,000), the Anbarci Family Company Showcase Prize ($1,000), and the Best Elevator Pitch - Consumer ($500).
  • TransCrypts from the University of Toronto and Harvard University, a secure blockchain platform for sharing employee documents, won two awards — the Owl Investment Prize ($50,000) and the Best Elevator Pitch - Digital ($500) — for a total of $50,500 in prizes.
  • Advanced Optronics of Carnegie Mellon University, a health tech company that develops smart sensors to improve patient outcomes, won two awards — the Pediatric Device Prize ($25,000) and the OFW Law FDA Regulatory Strategy In-Kind Prize — for a total of more than $25,000 in cash and in-kind prizes.
  • EpiSLS — a novel medical device startup that's automating in-vivo allergy testing — of the University of Michigan won the $25,000 Pediatric Device Prize.
  • Farm-to-closet women's apparel brand Pareto of Stanford University won the $10,000 nCourage Courageous Women Entrepreneur Investment Prize.
  • EpiFresh of Rice University, which developed a protective produce coating material that reduces food waste, won three awards for a total of $27,000. The company won the Energy, Cleantech & Sustainability Prize ($25,000), the Anbarci Family Company Showcase Prize ($1,000), and the Overall Best Elevator Pitch ($1,000).
  • Mantel of MIT, which is developing a high temperature liquid phase carbon capture material, won two awards for a total of $28,000 in prizes. The company won the New Climate Ventures Investment Prize ($25,000) and the DK Innovation Prize ($3,000).
  • Invictus BCI — a health tech startup building a noninvasive brain computer interface tools — from MIT won the the RBPC Alumni Network NABACO Prize for a total of $10,000 in winnings.
  • Health care fintech solution Woobie of Brigham Young University won the $25,000 Urban Capital Network Investment Prize.
  • KLAW Industries of Binghamton University, which has designed a way to recycle glass into concrete, won the Anbarci Family Company Showcase Prize ($1,000) and the Best Elevator Pitch - Energy ($500) prizes for a total of $1,500 in awards.
  • Acorn Genetics of Northwestern University, which is better optimizing genetic data for patients, won second place for the wildcard round, which came with the Edward H. Molter Memorial Prize ($1,750).
  • AI-powered stroke prevention platform PLAKK from McGill University won third place for the wildcard round, which came with the Edward H. Molter Memorial Prize ($1,500).
These startups join the ranks of 269 successful RBPC alumni companies — with 50 exits, five IPOs, and over $4.6 billion raised. RBPC was established in 2001.
The Rice Business Plan Competition is back in person this year, and these are the 42 teams that will go head to head for investments and prizes. Photo courtesy of Rice University

Rice University's student startup competition names 42 teams to compete for over $1 million in prizes

ready to pitch

The Rice Alliance for Technology and Entrepreneurship and the Jones Graduate School of Business have announced the 42 student teams that will compete in the 2022 Rice Business Plan Competition, which returns to an in-person format on the Rice University campus in April.

Of the teams competing for more than $1 million in prizes and funding in this year's competition, six hail from Texas — two teams each from Rice University, University of Texas at Austin, and Texas A&M University. The student competitors represent 31 universities — including three from European universities. The 42 teams were narrowed down from over 400 applicants and divided into five categories: energy, cleantech and sustainability; life sciences and health care solutions; consumer products and services; hard tech; and digital enterprise.

This is the first in-person RBPC since 2019, and the university is ready to bring together the entrepreneurs and a community of over 250 judges, mentors, and investors to the competition.

“As we come out on the other side of a long and challenging two years, we're feeling a sense of renewal and energy as we look to the future and finding inspiration from the next generation of entrepreneurs who are building a better world,” says Catherine Santamaria, director of the RBPC, in a news release.

“This year's competition celebrates student founders with a strong sense of determination — founders who are ready to adapt, build and grow companies that can change the future,” she continues. “We hope their participation will provide guidance and inspiration for our community.”

According to a news release, this year's RBPC Qualifier Competition, which narrowed down Rice's student teams that will compete in the official competition, saw the largest number of applicants, judges, and participants in the competition’s history. The Rice Alliance awarded a total of $5,000 in cash prizes to the top three teams from the internal qualifier: EpiFresh, Green Room and Anvil Diagnostics. From those three, Rice teams EpiFresh and Green Room received invitations to compete in the 2022 RBPC..

The full list of student teams that will be competing April 7 to 9 this year include:

  • Acorn Genetics from Northwestern University
  • Advanced Optronics from Carnegie Mellon University
  • Aethero Space from University of Missouri
  • AImirr from University of Chicago
  • AiroSolve from UCLA
  • Algeon Materials from UC San Diego
  • Anise Health from Harvard University
  • Beyond Silicon from Arizona State University
  • Bold Move Beverages from University of Texas at Austin
  • Diamante from University of Verona
  • EarthEn from Arizona State University
  • Empower Sleep from University of Pennsylvania
  • EpiFresh from Rice University
  • EpiSLS from University of Michigan
  • Green Room from Rice University
  • Horizon Health Solutions from University of Arkansas
  • Hoth Intelligence from Thomas Jefferson University
  • INIA Biosciences from Boston University
  • Invictus BCI from MIT
  • Invitris from Technical University of Munich (TUM)
  • KLAW Industries from Binghamton University
  • LIDROTEC from RWTH Aachen
  • Locus Lock from University of Texas at Austin
  • LymphaSense from Johns Hopkins University
  • Mallard Bay Outdoors from Louisiana State University
  • Mantel from MIT
  • Olera from Texas A&M University
  • OpenCell AI from Weill Cornell Medicine
  • OraFay from UCLA
  • Pareto from Stanford University
  • Photonect Interconnect Solutions from University of Rochester
  • PLAKK from McGill University
  • PneuTech from Johns Hopkins University
  • Rola from UC San Diego
  • RotorX from Georgia Tech
  • SimulatED from Carnegie Mellon University
  • SuChef from University of Pennsylvania
  • Symetric Finance from Fairfield University
  • Teale from Texas A&M University
  • Team Real Talk from University at Buffalo
  • TransCrypts from Harvard University
  • Woobie from Brigham Young University
Last year's awards had 54 student teams competing virtually, with over $1.4 million in cash and prizes awarded. Throughout RBPC's history, competitors have gone onto raise more than $3.57 billion in capital and more than 259 RBPC alumni have successfully launched their ventures. Forty RBPC startups that have had successful exits through acquisitions or trading on a public market, per the news release.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston health tech innovator collaborates on promising medical device funded by DOD

team work

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect.

The team working on this new research seeks to minimize near-eventualities like blood clot formation, blood damage, and driveline complications such as infection and limitations in mobility. The four institutions will try to innovate with a device featuring new engineering designs, antithrombotic slippery hydrophilic coatings (SLIC), wireless power transfer systems, and magnetically levitated driving systems.

Wang and her team believe that the non-contact-bearing technology will help to decrease the risk of blood clotting and damage when implanting an LVAD. The IDEA Lab will test the efficacy and safety of the SLIC LVAD developed by the multi-institutional team with a lab-bench-based blood flow loop, but also in preclinical models.

“The Texas Heart Institute continues to be a leading center for innovation in mechanical circulatory support systems,” said Joseph G. Rogers, MD, the president and CEO of THI, in a press release.

“This award will further the development and testing of the SLIC LVAD, a device intended to provide an option for a vulnerable patient population and another tool in the armamentarium of the heart failure teams worldwide.”

If it works as hypothesized, the SLIC LVAD will improve upon current LVAD technology, which will boost quality of life for countless heart patients. But the innovation won’t stop there. Technologies that IDEA Lab is testing include wireless power transfer for medical devices and coatings to reduce blood clotting could find applications in many other technologies that could help patients live longer, healthier lives.

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."



An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

View All Listings